Monoamine Transporter Gene Polymorphisms and Antidepressant Response in Koreans With Late-Life Depression
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
CONTEXT: Polymorphisms in the serotonin transporter gene (5-HTT) may influence antidepressant response to selective serotonin reuptake inhibitors (SSRIs). The norepinephrine transporter (NET) is the analogous target for norepinephrine reuptake inhibitors (NRIs). OBJECTIVE: To determine whether antidepressant responses to SSRIs or NRIs are associated with genetic polymorphisms of the corresponding monoamine transporters. DESIGN, SETTING, AND PATIENTS: A 6-week naturalistic treatment study with blinded outcome evaluation of 241 Korean inpatients and outpatients with major depression at an academic psychiatry service. Patients were recruited to the study from March 1998 through February 2003. INTERVENTIONS: Treatment with an SSRI (fluoxetine or sertraline; n = 136) or an NRI (nortriptyline; n = 105) antidepressant. Adherence was assessed by measuring plasma concentration at 4 weeks. Patients were genotyped for s/l polymorphisms in 5-HTT promoter region (5-HTTLPR), 5-HTT intron 2 s/l variation, and NET G1287A variation of exon 9. MAIN OUTCOME MEASURES: An SSRI and NRI response (defined as > or =50% decrease in Hamilton Rating Scale for Depression score at 6 weeks). RESULTS: NRI response was associated with the NET G1287A polymorphism (odds ratio [OR], 7.54; 95% confidence interval [CI], 2.53-22.49; P<.001). An SSRI response was associated with the 5-HTT intron 2 s/l variation (OR, 20.11; 95% CI, 4.27-94.74; P<.001). The 5-HTTLPR was also associated with an SSRI response (OR, 3.34; 95% CI, 1.41-7.91; P = .006). In contrast to studies in white patients, the favorable allele for SSRI response was S 5-HTTLPR. The S 5-HTTLPR was associated also with NRI response (OR, 3.73; 95% CI, 1.32-10.53; P = .01). The NET polymorphism was not associated with an SSRI response. The NET G1287A GG genotype (56% of the population) was associated with better response to the NRI (83.3% [35/42]) than to SSRI (58.7% [44/75]) (OR, 3.52; 95% CI, 1.39-8.95; P = .006). Some genotype combinations were associated with high rates of antidepressant response and others with low rates of response. CONCLUSIONS: Monoamine transporter gene polymorphisms were associated with response to antidepressants with homologous monoamine transporter targets. Combinations of polymorphisms were informative for response and nonresponse. Confirmation of these preliminary findings would permit refined pharmacogenetic selection of antidepressant treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Allelic Variation of Human Serotonin Transporter Gene Expression
Heils, A., Teufel, A., Petri, S., Stöber, G., Riederer, P., Bengel, D., & Lesch, K. P. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66062621.x · Cited by 2,221
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705 · cited 2×
“In addition to treatment response, we also monitored adverse events to antidepressants by the UKU Side Effect Rating Scale.16”
MethodAnderson, I. M. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00092-0 · Cited by 940
Recent developments and current controversies in depression
Ebmeier, K. P., Donaghey, C., & Steele, J. D. (2006) · The Lancet · doi:10.1016/s0140-6736(06)67964-6 · Cited by 434 · cited 1×
“Nevertheless, thenaturalisticdesign of our study reflects the de facto conditions of managing depression in primary care, in which drugs are a firstline treatment and placebo is not used.(48)”
BackgroundKeller, M. B. (2003) · JAMA · doi:10.1001/jama.289.23.3152 · Cited by 388 · cited 1×
“Remission was defined as a HAM-D score of less than 8 at 6 weeks.(19) FIGURE 1 shows the flow of patients through the study.”
BackgroundLate-onset major depression: clinical and treatment-response variability
Driscoll, H. C., Basinski, J., Mulsant, B. H., Butters, M. A., Dew, M. A., Houck, P. R., Mazumdar, S., Miller, M. D., Pollock, B. G., Stack, J. A., et al. (2005) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1334 · Cited by 57
Cited by
Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder
Kato, M., & Serretti, A. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.116 · Cited by 450
Personalized Medicine for Depression: Can We Match Patients With Treatments?
Simon, G. E., & Perlis, R. H. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09111680 · Cited by 365
Porcelli, S., Fabbri, C., & Serretti, A. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.10.003 · Cited by 331
“(data for two studies (Joyce et al., 2003; Kim et al., 2006) are different since for unknown reason Taylor et al.”
BackgroundInfluentialPersonalized medicine in psychiatry: problems and promises
Ozomaro, U., Wahlestedt, C., & Nemeroff, C. B. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-132 · Cited by 270
Genetic predictors of response to antidepressants in the GENDEP project
Uher, R., Huezo-Diaz, P., Perroud, N., Smith, R., Rietschel, M., Mors, O., Hauser, J., Maier, W., Kozel, D., Henigsberg, N., et al. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.12 · Cited by 226
Metadata
- Authors
- Kim, H., Lim, S.-W., Kim, S., Kim, J.-W., Chang, Y. H., Carroll, B. J., & Kim, D. K.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2006-10-04
- Volume
- 296
- Issue
- 13
- Pages
- 1609
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2049098623
- Cited by
- 202
- References
- 6
- FWCI
- 6.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Monoamine Transporter Gene Polymorphisms and Antidepressant Response in Koreans With Late-Life Depression. https://app.cochat.ai/papers/10.1001/jama.296.13.1609
- The paper
- Kim, H., Lim, S.-W., Kim, S., Kim, J.-W., Chang, Y. H., Carroll, B. J., & Kim, D. K. (2006). Monoamine Transporter Gene Polymorphisms and Antidepressant Response in Koreans With Late-Life Depression. JAMA. https://doi.org/10.1001/jama.296.13.1609
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.